Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment

Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation

(2013) Scott M. Palmer   ANNALS OF INTERNAL MEDICINE

Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+T-Cell Response in Allogeneic Stem Cell Transplant Recipients

(2012) María Ángeles Clari et al.   Clinical and Vaccine Immunology

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis

(2012) Guy Boivin et al.   JOURNAL OF CLINICAL VIROLOGY

Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver Transplantation

(2012) Seung H. Kang et al.   JOURNAL OF INFECTIOUS DISEASES

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

(2012) Mohamed A Kharfan-Dabaja et al.   LANCET INFECTIOUS DISEASES

Cytomegalovirus Disease in Kidney Transplant Recipients: Incidence, Clinical Profile, and Risk Factors

(2012) E. Cordero et al.   TRANSPLANTATION PROCEEDINGS

Post–Renal Transplant Cytomegalovirus Infection: Study of Risk Factors

(2012) V.B. Kute et al.   TRANSPLANTATION PROCEEDINGS

First Report of Successful Treatment of Multidrug-Resistant Cytomegalovirus Disease with the Novel Anti-CMV Compound AIC246

(2011) D. R. Kaul et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials

(2011) D. C. Brennan et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients

(2011) W. Bosch et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Antibody-dependent anti-cytomegalovirus activity of human    T cells expressing CD16 (Fc RIIIa)

(2011) L. Couzi et al.   BLOOD

Factors Contributing to Variability of Quantitative Viral PCR Results in Proficiency Testing Samples: a Multivariate Analysis

(2011) R. T. Hayden et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial

(2011) C. Ashley Finlen Copeland et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?

(2011) Jong Man Kim et al.   LIVER TRANSPLANTATION

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

(2011) A.A. Boudreault et al.   Transplant Infectious Disease

The risk of cytomegalovirus recurrence after kidney transplantation

(2011) Ilkka Helanterä et al.   TRANSPLANT INTERNATIONAL

Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients

(2011) Hans-Arne Myhre et al.   TRANSPLANTATION

Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

(2011) Luiz F. Lisboa et al.   TRANSPLANTATION

Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial

(2011) Oliver Witzke et al.   TRANSPLANTATION

Clinical Usefulness of Plasma Quantitative Polymerase Chain Reaction Assay: Diagnosis of Cytomegalovirus Infection in Kidney Transplant Recipients

(2011) J.-Y. Rhee et al.   TRANSPLANTATION PROCEEDINGS

Influence of Cytomegalovirus Disease in Outcome of Solid Organ Transplant Patients

(2011) L. Linares et al.   TRANSPLANTATION PROCEEDINGS

Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation

(2011) David R. Snydman et al.   TRANSPLANTATION PROCEEDINGS

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis

(2010) A. C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Antiviral Drug Resistance of Human Cytomegalovirus

(2010) N. S. Lurain et al.   CLINICAL MICROBIOLOGY REVIEWS

QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

(2010) Stefano Giulieri et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

(2010) Atul Humar et al.   TRANSPLANTATION

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response

(2010) Luiz F. Lisboa et al.   TRANSPLANTATION

Interlaboratory Comparison of Cytomegalovirus Viral Load Assays

(2009) X. L. Pang et al.   AMERICAN JOURNAL OF TRANSPLANTATION